{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'MMF adherence', 'Pegloticase Antibody/Mechanistic Study', 'Gout Flare Prophylaxis', 'IR Prophylaxis / Assess for IRs', 'Administer pegloticase infusion, per site guidelines', 'Following completion of Visit 11 participants will continue on pegloticase for an additional twelve weeks without', 'immune modulating therapy to evaluate the longer term benefits of this approach. In Phase 2 participants will continue', 'with pegloticase infusions every 2 weeks.', 'Visit 12 (14 weeks)', 'Obtain and record vital signs, including pulse rate, blood pressure, and body temperature', 'Targeted Physical Exam and joint assessment', 'Review / update concomitant medications', 'Assess any AEs, and record', 'Gout Flare assessment', 'Laboratory Assessments', 'CBC with diff', 'sUA', 'Pregnancy test for premenopausal women', 'CMP', 'Gout Flare Prophylaxis', 'IR Prophylaxis / Assess for IRs', 'Administer pegloticase infusion, per site guidelines.', 'Visit 13 (16 weeks)', 'Obtain and record vital signs, including pulse rate, blood pressure, and body temperature', 'Targeted Physical Exam and joint assessment', 'Review / update concomitant medications', 'Assess any AEs, and record', 'Gout Flare Assessment', 'PROs (PROMIS-29 & GIS instrument)', 'Laboratory Assessments', 'CBC with diff', 'sUA', 'Pregnancy test for premenopausal women', 'CMP', 'Gout Flare Prophylaxis', 'IR Prophylaxis / Assess for IRs', 'Administer pegloticase infusion, per site guidelines', 'Visit 14 (18 weeks)', 'Obtain and record vital signs, including pulse rate, blood pressure, and body temperature', 'Targeted Physical Exam and joint assessment', 'Review concomitant medications, and record', '22']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'Assess any AEs, and record', 'Gout Flare Assessment', 'Laboratory Assessments', 'CBC with diff', 'sUA', 'Pregnancy test for premenopausal women', 'CMP', 'Pegloticase Antibody/Mechanistic Study', 'Gout Flare Prophylaxis', 'IR Prophylaxis /Assess for IRs', 'Administer pegloticase infusion, per site guidelines', 'Visit 15 (20 weeks)', 'Obtain and record vital signs, including pulse rate, blood pressure, and body temperature', 'Targeted Physical Exam and joint assessment', 'Review concomitant medications, and record', 'Assess any AEs, and record', 'Gout Flare assessment', 'PROs (PROMIS-29 & GIS instrument)', 'Laboratory Assessments', 'CBC with diff', 'sUA', 'Pregnancy test for premenopausal women', 'CMP', 'Gout Flare Prophylaxis', 'IR Prophylaxis / Assess for IRs', 'Administer pegloticase infusion, per site guidelines', 'Visit 16 (22 weeks)', 'Obtain and record vital signs, including pulse rate, blood pressure, and body temperature', 'Targeted Physical Exam and joint assessment', 'Review concomitant medications, and record', 'Assess any AEs, and record', 'Gout Flare assessment', 'Laboratory Assessments', 'CBC with diff', 'sUA', 'Pregnancy test for premenopausal women', 'CMP', 'Gout Flare Prophylaxis', 'IR Prophylaxis /Assess for IRs', 'Administer pegloticase infusion, per site guidelines.', 'Visit 17 (24 weeks)', '23']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'Participants will complete a final physical exam and update their medical history since enrollment.', 'Obtain and record vital signs, including pulse rate, blood pressure, and body temperature', 'Review concomitant medications, and record', 'Assess any AEs, and record', 'PROs (PROMIS-29 & GIS instrument)', 'Physical exam', 'HEENT, and Neck', 'Cardiovascular', 'Respiratory', 'Gastrointestinal', 'Musculoskeletal', 'Neurologic', 'Integumentary', 'VS/Measurements', 'Laboratory Assessments', 'CBC with diff', 'sUA', 'Pregnancy test for premenopausal women', 'CMP', 'Pegloticase Antibody/Mechanistic Study', 'Following completion of Visit 17 participants will continue for an additional 12 weeks without pegloticase infusions for', 'anti-pegloticase antibody testing. In Phase 3, participants will continue with blood draws and banking of biospecimen', 'every 4 weeks.', 'Reminder: if a participant is discontinued from the study, they will move into long-term follow-up and will be asked to', 'complete visits 17, in addition to the three 1-month visits 18-20.', 'Visit 18 (28 weeks)', 'Participants will report 4 weeks following completion of Visit 17 for a blood draw and banking of biospecimen for anti-', 'pegloticase antibody testing.', 'Assessments', 'Adverse events', 'Pegloticase Antibody/Mechanistic Study', 'Visit 19 (32 weeks)', 'Participants will report 4 weeks following completion of Visit 18 for a blood draw and banking of biospecimen for anti-', 'pegloticase antibody testing.', 'Assessments', 'Adverse events', 'Pegloticase Antibody/Mechanistic Study', 'Visit 20 (36 weeks-Final/visit)', 'Participants will report 4 weeks following completion of Visit 19 for a blood draw and banking of biospecimen for anti-', 'pegloticase antibody testing.', 'Assessments', 'Adverse events', '24']\n\n###\n\n", "completion": "END"}